A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
暂无分享,去创建一个
S. Durrleman | J. Corvol | B. Couvy-Duchesne | Nicolas Villain | A. Darves-Bornoz | Y. Wu | B. Lekens | A. Schrag | L. Gantzer | R. Couronné | T. Nedelec | F. Monnet
[1] S. Durrleman,et al. Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records. , 2022, The Lancet. Digital health.
[2] Lin F. Yang,et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet. Public health.
[3] S. Durrleman,et al. Data-driven identification of health conditions associated with incident Alzheimer's disease dementia risk: a 15 years follow-up cohort from electronic health records in France and the United Kingdom , 2021, medRxiv.
[4] S. Fereshtehnejad,et al. Prodromal Parkinson disease subtypes — key to understanding heterogeneity , 2021, Nature Reviews Neurology.
[5] T. Foltynie,et al. Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes , 2020, Brain : a journal of neurology.
[6] D. Brooks,et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. , 2020, Brain : a journal of neurology.
[7] Naaheed Mukadam,et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.
[8] C. Carroll,et al. Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study , 2019, BMJ Open.
[9] K. Wirdefeldt,et al. Lipids, Apolipoproteins, and The Risk of Parkinson's Disease: A Prospective Cohort Study and a Mendelian Randomization Analysis. , 2019, Circulation research.
[10] A. Sinclair,et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype , 2019, Alzheimer's & Dementia.
[11] Daniela Berg,et al. Prodromal Parkinson's Disease: The Decade Past, the Decade to Come , 2019, Movement disorders : official journal of the Movement Disorder Society.
[12] P. Visscher,et al. Genome-wide association study of medication-use and associated disease in the UK Biobank , 2019, Nature Communications.
[13] M. Stamelou,et al. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[14] Yoshihiro Kokubo,et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.
[15] P. Donnelly,et al. The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.
[16] L. Petrucelli,et al. Converging pathways in neurodegeneration, from genetics to mechanisms , 2018, Nature Neuroscience.
[17] Nir Giladi,et al. Higher serum cholesterol and decreased Parkinson's disease risk: A statin‐free cohort study , 2018, Movement disorders : official journal of the Movement Disorder Society.
[18] D. Berlau,et al. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms , 2018, Translational Neurodegeneration.
[19] Yue Huang,et al. Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.
[20] David S. Park,et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.
[21] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[22] B. Boeve,et al. Lewy body dementias , 2015, The Lancet.
[23] F. Sacks,et al. MIND diet associated with reduced incidence of Alzheimer's disease , 2015, Alzheimer's & Dementia.
[24] Xuemei Huang,et al. Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study , 2015, Movement disorders : official journal of the Movement Disorder Society.
[25] T. Kawada. Predictors of dementia in Parkinson disease: A prospective cohort study , 2015, Neurology.
[26] R. Postuma,et al. Parkinson risk in idiopathic REM sleep behavior disorder , 2015, Neurology.
[27] S. Villapol,et al. Neuroprotective effects of angiotensin receptor blockers. , 2015, American journal of hypertension.
[28] K. Walters,et al. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study , 2015, The Lancet Neurology.
[29] R. Postuma,et al. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies , 2013, Movement disorders : official journal of the Movement Disorder Society.
[30] P. Hedera,et al. Pharmacotherapy of Essential Tremor , 2013, Journal of central nervous system disease.
[31] J. Dartigues,et al. Benzodiazepine use and risk of dementia: prospective population based study , 2012, BMJ : British Medical Journal.
[32] A. Bourke,et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. , 2011, Informatics in primary care.
[33] P. Rose,et al. Validity of diagnostic coding within the General Practice Research Database: a systematic review. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.
[34] L. Werdelin,et al. Constipation in neurological diseases , 2003, Journal of neurology, neurosurgery, and psychiatry.